A Phase 1 interventional study of HRS-8427 in Healthy Cninese Adult Male, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment
To evaluate the absorption, metabolism and excretion after a single intravenous infusion of [14C]HRS-8427 in healthy Chinese subjects
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 559 studies on the registry; 85 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: HRS-8427
\[14C\] HRS-8427 for injection
The total radioactive recovery rate and cumulative total radioactive recovery rate at each time interval in excreta (urine and feces)
Time frame: 0~120hours
The percentage (%AUC) of the potent drug and its metabolites in plasma, urine and feces to the administered dose
Time frame: 0~120hours
Tmax
Time frame: 0~48hours
Cmax
Time frame: 0~48hours
t1/2
Time frame: 0~48hours
MRT
Time frame: 0~48hours
AUC
Time frame: 0~48hours
Tmax
Time frame: 0~48hours
Cmax
Time frame: 0~48hours
MRT
Time frame: 0~48hours
AUC
Time frame: 0~48hours
t1/2
Time frame: 0~48hours
Adverse events
Time frame: 0~120hours
Plan to share: Undecided
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu HengRui Medicine Co., Ltd.